Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.

Fiche publication


Date publication

juin 2022

Journal

Journal of thoracic disease

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Dr BOIDOT Romain, Dr FOUCHER Pascal, Pr GHIRINGHELLI François, Dr FAVIER Laure, Pr BONNIAUD Philippe


Tous les auteurs :
Tankere P, Boidot R, Bonniaud P, Zouak A, Foucher P, Milliere A, Bertaut A, Favier L, Lagrange A, Ghiringhelli F, Kaderbhai CG, Fraisse C

Résumé

The best management for rare epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung carcinoma (NSCLC) remains uncertain. The literature indicates that response to usual treatment could differ in certain subgroups such as exon 20 insertion/duplication (E20ID), other single uncommon mutation (OSUM), and EGFR complex mutation (ECM).

Mots clés

Lung cancer, non-small cell lung carcinoma (NSCLC), rare EGFR mutation, uncommon epidermal growth factor receptor (EGFR) mutation

Référence

J Thorac Dis. 2022 06;14(6):2034-2044